Cerity Partners
RARE icon

Cerity Partners’s Ultragenyx Pharmaceutical RARE Stock Holding History

Cerity Partners’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.51M Buy
105,055
+73,163
+229% +$1.82M ﹤0.01% 1279
2026
Q1 		$668K Buy
31,892
+16,214
+103% +$365K ﹤0.01% 2106
2025
Q4 		$361K Buy
+15,678
New +$516K ﹤0.01% 2295
2024
Q4 		– Sell
-31,919
Closed -$1.77M – 2564
2024
Q3 		$1.77M Buy
+31,919
New +$1.63M ﹤0.01% 1147

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Cerity Partners's RARE Position: Q2 2026 in Review

Cerity Partners increased its Ultragenyx Pharmaceutical (RARE) stake by 229% in Q2 2026, buying an estimated $1.82M and bringing the position to 105,055 shares worth $3.51M. The position accounts for ﹤0.01% of the portfolio, ranked #1279.

Cerity Partners first reported a position in RARE in Q3 2024 and has held it in 4 quarters since. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Cerity Partners held 105,055 shares of Ultragenyx Pharmaceutical worth $3.51M as of Q2 2026.
  • Cerity Partners bought 73,163 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $1.82M.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #1279 holding.
  • Cerity Partners first reported a position in Ultragenyx Pharmaceutical in Q3 2024 and has held it in 4 quarters since.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.